A Phase II Randomized Controlled Trial Evaluating the Impact of Therapeutic Drug Monitoring (TDM) on Virologic Response to a Salvage Regimen in Subjects With a Normalized Inhibitory Quotient (NIQ) Less Than or Equal to 1 to One or More Protease Inhibitors.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Antiretrovirals; HIV protease inhibitors
- Indications HIV-1 infections
- Focus Therapeutic Use
- 13 Jul 2010 Biomarkers information updated
- 28 Jan 2009 Results were published in AIDS.
- 16 Dec 2008 Status changed from active, no longer recruiting to completed.